AZD4547 + MEDI4736 + Olaparib + AZD1775 + Vistusertib + AZD9150 + Selumetinib
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Muscle Invasive Bladder Cancer
Conditions
Muscle Invasive Bladder Cancer
Trial Timeline
Dec 28, 2016 → Jan 30, 2026
NCT ID
NCT02546661About AZD4547 + MEDI4736 + Olaparib + AZD1775 + Vistusertib + AZD9150 + Selumetinib
AZD4547 + MEDI4736 + Olaparib + AZD1775 + Vistusertib + AZD9150 + Selumetinib is a phase 1 stage product being developed by AstraZeneca for Muscle Invasive Bladder Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT02546661. Target conditions include Muscle Invasive Bladder Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02546661 | Phase 1 | Active |
Competing Products
20 competing products in Muscle Invasive Bladder Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pegylated liposomal doxorubicin (PLD) + PD-1 | CSPC Pharmaceutical Group Limited | Phase 2 | 51 |
| Enfortumab vedotin + Pembrolizumab | Astellas Pharma | Phase 2 | 52 |
| Enfortumab Vedotin + Pembrolizumab | Astellas Pharma | Phase 2 | 52 |
| Pembrolizumab + Enfortumab Vedotin | Astellas Pharma | Phase 3 | 77 |
| Eperisone | Eisai | Phase 3 | 77 |
| LY2495655 + Placebo | Eli Lilly | Phase 2 | 52 |
| HRS-9190 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| HRS-9190 for Injection | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Botulinum Toxin Type A | AbbVie | Phase 3 | 77 |
| BOTOX + Placebo | AbbVie | Phase 3 | 77 |
| BOTOX + Placebo | AbbVie | Phase 3 | 77 |
| BOTOX + Placebo for BOTOX | AbbVie | Phase 3 | 77 |
| BOTOX + Placebo | AbbVie | Phase 3 | 77 |
| Durvalumab + Tremelimumab + Enfortumab Vedotin | AstraZeneca | Phase 3 | 77 |
| Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG) | AstraZeneca | Phase 3 | 77 |
| Durvalumab + Oleclumab | AstraZeneca | Phase 1 | 33 |
| Durvalumab + Cisplatin + Gemcitabine | AstraZeneca | Phase 3 | 77 |
| Durvalumab + BCG | AstraZeneca | Phase 3 | 77 |
| Durvalumab + Monalizumab | AstraZeneca | Phase 2 | 52 |
| Durvalumab (Imfinzi) + Tremelimumab | AstraZeneca | Phase 2 | 52 |